International Aids Vaccine Initiative

Merck Sharp + Dohme Corp.

Maoli Yuan

Christopher Lee Parks

Kevin Wright

Christy Jurgens

Aaron J Wilson

Xinsheng Zhang

Maria J Chiuchiolo

Svetlana Rabinovich

Ivo Lorenz

Makoto Inoue

Simon Hoffenberg

Hiroto Hara

Arban Domi

Takashi Hironaka

Josephine Helena Cox

Eddy Sayeed

Angela Grazia Lombardo

Andrew J Bett

Sanjay K Phogat

Amy Espeseth

Ross W B Lindsay

Mark Feinberg

Ivo C Lorenz

Kevin J Wright

Christy K Jurgens

The present disclosure provides Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) vaccines, recombinant vesicular stomatitis virus (VSV) vectors encoding the SARS-CoV-2 spike (S) protein or an immunogenic variant thereof, recombinant replicable VSV particles having a SARS-CoV-2 S protein or an immunogenic variant thereof on the surface of the particles, and immunogenic recombinant proteins comprising a SARS-CoV-2 S protein or a variant thereof. Immunogenic compositions comprising the SARS-CoV-2 vaccines, the recombinant VSV vectors, the recombinant replicable VSV particles and/or the immunogenic recombinant proteins may be used for inducing an immune response to the SARS-CoV-2, preventing infection by the SARS-CoV-2, vaccinating against the SARS-CoV-2 and/or producing adaptive mutants of the recombinant replicable VSV particles.

Replication-competent attenuated chimeric VSV vectors encoding immunogenic SARS-CoV-2 spike proteins

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines as well as the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

Vesicular stomatitis virus and virus rescue system

The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.

Optimized HIV envelope gene and expression thereof

The present invention relates to methods of developing gene inserts that are more compatible with the host vectors by modifying a protein sequence to lessen potential interference with vector propagation while ensuring that the protein is expressed and processed efficiently and maintains desired structural features, and designing a gene with a nucleotide sequence that resembles the base composition of the host vector genome.

Methods to improve vector expression and genetic stability

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

Recombinant viral vectors

Growing community of inventors

Brooklyn, NY, United States of America

Maoli Yuan